We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| IN8bio Inc | NASDAQ:INAB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0432 | 18.77% | 0.2733 | 0.2512 | 1.50 | 0.273 | 0.23 | 0.23 | 1,457,211 | 05:00:10 |
From Aug 2024 to Oct 2024
H.C. Wainwright 26th Annual Global Investment ConferenceFormat Fireside ChatDate/Time Monday, September 9, 2024, at 2:30 p.m. ET.
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investor & Corporate ContactGlenn Schulman, PharmD, MPHIN8bio, Inc.203.494.7411gdschulman@IN8bio.com
Media ContactKimberly HaKKH Advisors917.291.5744kimberly.ha@kkhadvisors.com
1 Year IN8bio Chart |
1 Month IN8bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
